reference code: gmdhc3574idb publication date: may 2013 … · sample pancreatic cancer –...
TRANSCRIPT
![Page 1: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/1.jpg)
SAMPLE
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Pancreatic Cancer – Pipeline Review, H1 2013
Reference Code: GMDHC3574IDB
Publication Date: May 2013
![Page 2: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/2.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Table of Contents
Table of Contents .................................................................................................................................................................................... 2
List of Tables ...................................................................................................................................................................................... 8
List of Figures .................................................................................................................................................................................. 13
Introduction ........................................................................................................................................................................................... 14
Global Markets Direct Report Coverage ......................................................................................................................................... 14
Pancreatic Cancer Overview................................................................................................................................................................ 15
Therapeutics Development .................................................................................................................................................................. 16
An Overview of Pipeline Products for Pancreatic Cancer .............................................................................................................. 16
Pancreatic Cancer Therapeutics under Development by Companies ................................................................................................ 18
Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes ................................................................................. 32
Late Stage Products ............................................................................................................................................................................. 35
Comparative Analysis ...................................................................................................................................................................... 35
Mid Clinical Stage Products ................................................................................................................................................................. 36
Comparative Analysis ...................................................................................................................................................................... 36
Early Clinical Stage Products ............................................................................................................................................................... 37
Comparative Analysis ...................................................................................................................................................................... 37
Discovery and Pre-Clinical Stage Products ......................................................................................................................................... 38
Comparative Analysis ...................................................................................................................................................................... 38
Pancreatic Cancer Therapeutics – Products under Development by Companies .............................................................................. 39
Pancreatic Cancer Therapeutics – Products under Investigation by Universities/Institutes ............................................................... 59
Companies Involved in Pancreatic Cancer Therapeutics Development ............................................................................................. 62
Bristol-Myers Squibb Company ...................................................................................................................................................... 62
F. Hoffmann-La Roche Ltd. ............................................................................................................................................................. 63
Amgen Inc. ...................................................................................................................................................................................... 64
Sanofi-Aventis ................................................................................................................................................................................. 65
AstraZeneca PLC ............................................................................................................................................................................ 66
Eli Lilly and Company ...................................................................................................................................................................... 67
Viralytics Ltd. ................................................................................................................................................................................... 68
GlaxoSmithKline plc ........................................................................................................................................................................ 69
Tekmira Pharmaceuticals Corp. ...................................................................................................................................................... 70
Genentech, Inc. ............................................................................................................................................................................... 71
Gilead Sciences, Inc. ....................................................................................................................................................................... 72
Biotest AG ....................................................................................................................................................................................... 73
Merck & Co., Inc. ............................................................................................................................................................................. 74
AbGenomics International, Inc. ....................................................................................................................................................... 75
Oxford BioMedica plc ...................................................................................................................................................................... 76
Plexxikon Inc. .................................................................................................................................................................................. 77
FibroGen, Inc. .................................................................................................................................................................................. 78
MediGene AG .................................................................................................................................................................................. 79
Nanotherapeutics, Inc. .................................................................................................................................................................... 80
Prolexys Pharmaceuticals, Inc. ....................................................................................................................................................... 81
ZIOPHARM Oncology, Inc. ............................................................................................................................................................. 82
![Page 3: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/3.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Novartis AG ..................................................................................................................................................................................... 83
Samyang Corporation ..................................................................................................................................................................... 84
Aphios Corporation .......................................................................................................................................................................... 85
Astellas Pharma Inc. ....................................................................................................................................................................... 86
CK Life Sciences Int'l., (Holdings) Inc. ............................................................................................................................................ 87
Eisai Co., Ltd. .................................................................................................................................................................................. 88
SuperGen, Inc. ................................................................................................................................................................................ 89
Taiho Pharmaceutical Co., Ltd. ....................................................................................................................................................... 90
Zeria Pharmaceutical Co Ltd ........................................................................................................................................................... 91
Silence Therapeutics plc. ................................................................................................................................................................ 92
Exelixis, Inc. ..................................................................................................................................................................................... 93
Aduro BioTech ................................................................................................................................................................................. 94
Celgene Corporation ....................................................................................................................................................................... 95
Bayer AG ......................................................................................................................................................................................... 96
Incyte Corporation ........................................................................................................................................................................... 97
Halozyme Therapeutics .................................................................................................................................................................. 98
Merck KGaA .................................................................................................................................................................................... 99
Advaxis, Inc. .................................................................................................................................................................................. 100
EntreMed, Inc. ............................................................................................................................................................................... 101
Momenta Pharmaceuticals, Inc. .................................................................................................................................................... 102
Anavex Life Sciences Corp. .......................................................................................................................................................... 103
ValiRx Plc ...................................................................................................................................................................................... 104
ImmunoCellular Therapeutics, Ltd. ............................................................................................................................................... 105
IMMUNOMEDICS, INC ................................................................................................................................................................. 106
Lorus Therapeutics Inc .................................................................................................................................................................. 107
Marshall Edwards, Inc. .................................................................................................................................................................. 108
MethylGene Inc ............................................................................................................................................................................. 109
Bionomics Limited ......................................................................................................................................................................... 110
Molecular Insight Pharmaceuticals, Inc. ....................................................................................................................................... 111
Northwest Biotherapeutics, Inc. .................................................................................................................................................... 112
Oncolytics Biotech Inc. .................................................................................................................................................................. 113
Patrys Limited ................................................................................................................................................................................ 114
Peregrine Pharmaceuticals, Inc. ................................................................................................................................................... 115
Critical Outcome Technologies Inc. .............................................................................................................................................. 116
La Jolla Pharmaceutical Company ............................................................................................................................................... 117
Telik, Inc. ....................................................................................................................................................................................... 118
VioQuest Pharmaceuticals, Inc. .................................................................................................................................................... 119
CytRx Corporation ......................................................................................................................................................................... 120
Champions Biotechnology, Inc. .................................................................................................................................................... 121
Oncogenex Pharmaceuticals, Inc. ................................................................................................................................................ 122
Pharmacyclics, Inc. ....................................................................................................................................................................... 123
ProMetic Life Sciences Inc. ........................................................................................................................................................... 124
Green Cross Corporation .............................................................................................................................................................. 125
OncoTherapy Science, Inc. ........................................................................................................................................................... 126
![Page 4: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/4.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4)
Quest PharmaTech Inc. ................................................................................................................................................................ 127
Threshold Pharmaceuticals, Inc. ................................................................................................................................................... 128
Synta Pharmaceuticals Corp. ........................................................................................................................................................ 129
CrystalGenomics, Inc. ................................................................................................................................................................... 130
Natco Pharma Limited ................................................................................................................................................................... 131
Sareum Holdings plc ..................................................................................................................................................................... 132
DiaMedica Inc. ............................................................................................................................................................................... 133
NanoCarrier Co., Ltd. .................................................................................................................................................................... 134
Rexahn Pharmaceuticals, Inc. ...................................................................................................................................................... 135
MabVax Therapeutics, Inc. ........................................................................................................................................................... 136
Nanobiotix ...................................................................................................................................................................................... 137
Morphotek, Inc. .............................................................................................................................................................................. 138
Cancer Research Technology Limited .......................................................................................................................................... 139
Antisense Pharma GmbH ............................................................................................................................................................. 140
Colby Pharmaceutical Company ................................................................................................................................................... 141
Wilex AG ........................................................................................................................................................................................ 142
INSYS Therapeutics, Inc. .............................................................................................................................................................. 143
Aurigene Discovery Technologies Limited .................................................................................................................................... 144
Philogen S.p.A. .............................................................................................................................................................................. 145
Multimmune GmbH ....................................................................................................................................................................... 146
Nerviano Medical Sciences S.r.l. .................................................................................................................................................. 147
Wellstat Therapeutics Corporation ................................................................................................................................................ 148
Hutchison MediPharma Limited .................................................................................................................................................... 149
ERYtech Pharma ........................................................................................................................................................................... 150
Advantagene, Inc. ......................................................................................................................................................................... 151
Alethia Biotherapeutics Inc. ........................................................................................................................................................... 152
NormOxys, Inc. .............................................................................................................................................................................. 153
Ascenta Therapeutics, Inc. ............................................................................................................................................................ 154
Gene Signal International SA. ....................................................................................................................................................... 155
Heat Biologics, Inc. ........................................................................................................................................................................ 156
MacroGenics, Inc. ......................................................................................................................................................................... 157
Antyra, Inc. .................................................................................................................................................................................... 158
OncoMed Pharmaceuticals, Inc. ................................................................................................................................................... 159
TetraLogic Pharmaceuticals .......................................................................................................................................................... 160
Azaya Therapeutics, Inc. ............................................................................................................................................................... 161
Merrimack Pharmaceuticals, Inc. .................................................................................................................................................. 162
Nobelpharma Co., Ltd. .................................................................................................................................................................. 163
INNOPHARMAX, INC. .................................................................................................................................................................. 164
RESprotect GmbH ......................................................................................................................................................................... 165
Jennerex Biotherapeutics, Inc. ...................................................................................................................................................... 166
Stemline Therapeutics, Inc. ........................................................................................................................................................... 167
Axcentua Pharmaceuticals AB ...................................................................................................................................................... 168
BioCancell Therapeutics, Inc. ....................................................................................................................................................... 169
Cornerstone Pharmaceuticals, Inc. ............................................................................................................................................... 170
![Page 5: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/5.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(5)
Onconova Therapeutics, Inc ......................................................................................................................................................... 171
Pharminox Limited ......................................................................................................................................................................... 172
Viral Genetics, Inc. ........................................................................................................................................................................ 173
KangLaiTe USA ............................................................................................................................................................................. 174
NovaLead Pharma Pvt. Ltd. .......................................................................................................................................................... 175
Esperance Pharmaceuticals, Inc. ................................................................................................................................................. 176
Omeros Corporation ...................................................................................................................................................................... 177
Transtech Pharma, Inc. ................................................................................................................................................................. 178
Welichem Biotech Inc. ................................................................................................................................................................... 179
Oncolys BioPharma Inc. ................................................................................................................................................................ 180
Globeimmune, Inc. ........................................................................................................................................................................ 181
NewLink Genetics Corporation ..................................................................................................................................................... 182
Tragara Pharmaceuticals, Inc. ...................................................................................................................................................... 183
PharmaMar, S.A. ........................................................................................................................................................................... 184
CG Therapeutics, Inc. ................................................................................................................................................................... 185
Quintessence Biosciences, Inc. .................................................................................................................................................... 186
AmpliMed Corporation................................................................................................................................................................... 187
AB Science .................................................................................................................................................................................... 188
Tigris Pharmaceuticals, Inc. .......................................................................................................................................................... 189
Genelux Corporation ..................................................................................................................................................................... 190
Lipopharma .................................................................................................................................................................................... 191
Nereus Pharmaceuticals, Inc. ....................................................................................................................................................... 192
Medisyn Technologies, Inc. ........................................................................................................................................................... 193
Oncovir, Inc. .................................................................................................................................................................................. 194
Keystone Nano, Inc. ...................................................................................................................................................................... 195
Perseus Proteomics, Inc. .............................................................................................................................................................. 196
Pique Therapeutics ....................................................................................................................................................................... 197
3-V Biosciences, Inc. ..................................................................................................................................................................... 198
Cancer Therapeutics CRC Pty Ltd ................................................................................................................................................ 199
Eleison Pharmaceuticals, Inc. ....................................................................................................................................................... 200
Targa Therapeutics Corp. ............................................................................................................................................................. 201
NuCana BioMed Limited ............................................................................................................................................................... 202
KAEL-GemVax .............................................................................................................................................................................. 203
Nuvilex, Inc. ................................................................................................................................................................................... 204
iCeutica, Inc. .................................................................................................................................................................................. 205
Mebiopharm Co., Ltd. .................................................................................................................................................................... 206
Polaris Group ................................................................................................................................................................................. 207
DEKK-TEC, Inc. ............................................................................................................................................................................ 208
IkerChem S.L................................................................................................................................................................................. 209
Regulon Inc. .................................................................................................................................................................................. 210
TAU Therapeutics, LLC ................................................................................................................................................................. 211
Gradalis Inc. .................................................................................................................................................................................. 212
CytoVac A/S .................................................................................................................................................................................. 213
Oncozyme Pharma Inc. ................................................................................................................................................................. 214
![Page 6: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/6.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(6)
CytomX, LLC. ................................................................................................................................................................................ 215
Pancreatic Cancer – Therapeutics Assessment ................................................................................................................................ 216
Assessment by Monotherapy Products ........................................................................................................................................ 216
Assessment by Combination Products ......................................................................................................................................... 217
Assessment by Route of Administration ....................................................................................................................................... 218
Assessment by Molecule Type ..................................................................................................................................................... 221
Drug Profiles ....................................................................................................................................................................................... 224
ganitumab - Drug Profile ............................................................................................................................................................... 224
Product Description .................................................................................................................................................................. 224
Mechanism of Action ................................................................................................................................................................ 224
R&D Progress ........................................................................................................................................................................... 224
paclitaxel albumin-bound - Drug Profile ........................................................................................................................................ 227
Product Description .................................................................................................................................................................. 227
Mechanism of Action ................................................................................................................................................................ 227
R&D Progress ........................................................................................................................................................................... 227
glufosfamide - Drug Profile ............................................................................................................................................................ 229
Product Description .................................................................................................................................................................. 229
Mechanism of Action ................................................................................................................................................................ 229
R&D Progress ........................................................................................................................................................................... 229
edotreotide labeled yttrium 90 - Drug Profile ................................................................................................................................ 231
Product Description .................................................................................................................................................................. 231
Mechanism of Action ................................................................................................................................................................ 231
R&D Progress ........................................................................................................................................................................... 231
tertomotide - Drug Profile .............................................................................................................................................................. 233
Product Description .................................................................................................................................................................. 233
Mechanism of Action ................................................................................................................................................................ 233
R&D Progress ........................................................................................................................................................................... 233
TH-302 - Drug Profile .................................................................................................................................................................... 235
Product Description .................................................................................................................................................................. 235
Mechanism of Action ................................................................................................................................................................ 235
R&D Progress ........................................................................................................................................................................... 235
irinotecan hydrochloride nanoliposomal - Drug Profile ................................................................................................................. 242
Product Description .................................................................................................................................................................. 242
Mechanism of Action ................................................................................................................................................................ 242
R&D Progress ........................................................................................................................................................................... 242
rigosertib sodium - Drug Profile .................................................................................................................................................... 244
Product Description .................................................................................................................................................................. 244
Mechanism of Action ................................................................................................................................................................ 244
R&D Progress ........................................................................................................................................................................... 244
algenpantucel-L - Drug Profile ...................................................................................................................................................... 247
Product Description .................................................................................................................................................................. 247
Mechanism of Action ................................................................................................................................................................ 247
R&D Progress ........................................................................................................................................................................... 247
elpamotide - Drug Profile .............................................................................................................................................................. 249
![Page 7: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/7.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(7)
Product Description .................................................................................................................................................................. 249
Mechanism of Action ................................................................................................................................................................ 249
R&D Progress ........................................................................................................................................................................... 249
masitinib - Drug Profile .................................................................................................................................................................. 251
Product Description .................................................................................................................................................................. 251
Mechanism of Action ................................................................................................................................................................ 251
R&D Progress ........................................................................................................................................................................... 251
TH-302 + [gemcitabine hydrochloride] - Drug Profile ................................................................................................................... 253
Product Description .................................................................................................................................................................. 253
Mechanism of Action ................................................................................................................................................................ 253
R&D Progress ........................................................................................................................................................................... 253
nimotuzumab - Drug Profile .......................................................................................................................................................... 255
Product Description .................................................................................................................................................................. 255
Mechanism of Action ................................................................................................................................................................ 255
R&D Progress ........................................................................................................................................................................... 255
liposomal cisplatin - Drug Profile ................................................................................................................................................... 258
Product Description .................................................................................................................................................................. 258
Mechanism of Action ................................................................................................................................................................ 258
R&D Progress ........................................................................................................................................................................... 258
uridine triacetate - Drug Profile ..................................................................................................................................................... 260
Product Description .................................................................................................................................................................. 260
Mechanism of Action ................................................................................................................................................................ 260
R&D Progress ........................................................................................................................................................................... 260
(tegafur + gimeracil + oteracil potassium) - Drug Profile .............................................................................................................. 262
Product Description .................................................................................................................................................................. 262
Mechanism of Action ................................................................................................................................................................ 262
R&D Progress ........................................................................................................................................................................... 262
brivudine - Drug Profile ................................................................................................................................................................. 265
Product Description .................................................................................................................................................................. 265
Mechanism of Action ................................................................................................................................................................ 265
R&D Progress ........................................................................................................................................................................... 265
OCV-C01 - Drug Profile ................................................................................................................................................................ 267
Product Description .................................................................................................................................................................. 267
Mechanism of Action ................................................................................................................................................................ 267
R&D Progress ........................................................................................................................................................................... 267
Polyclonal Antibody Stimulator - Drug Profile ............................................................................................................................... 268
Product Description .................................................................................................................................................................. 268
Mechanism of Action ................................................................................................................................................................ 268
R&D Progress ........................................................................................................................................................................... 268
Pancreatic Cancer Therapeutics – Drug Profile Updates .................................................................................................................. 269
Pancreatic Cancer Therapeutics – Discontinued Products ............................................................................................................... 293
Pancreatic Cancer Therapeutics - Dormant Products ....................................................................................................................... 297
Pancreatic Cancer – Product Development Milestones .................................................................................................................... 309
Featured News & Press Releases ................................................................................................................................................ 309
![Page 8: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/8.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(8)
Nov 14, 2012: NewLink Genetics Receives European Orphan Designation For Algenpantucel-L Immunotherapy To Treat Pancreatic Cancer .................................................................................................................................................................... 309
Nov 13, 2012: Tiltan Pharma Announces Enrollment Of First US Patient In Phase II Clinical Trial Of TL-118 For Treatment Of Metastatic Pancreatic Cancer .................................................................................................................................................. 309
Nov 12, 2012: Clovis Oncology Announces Outcome Of CO-101 In Pivotal LEAP Pancreatic Cancer Study ...................... 310
Nov 09, 2012: OncoMed Pharma Presents Clinical Data On Anti-Notch2/3 Program At EORTC-NCI-AACR Meeting ........ 311
Nov 09, 2012: Oncolytics Biotech Collaborators Present Positive Reolysin Trial Results And Research At EORTC-NCI-AACR Symposium ............................................................................................................................................................................... 312
Oct 31, 2012: Nuvilex Signs Contract With ViruSure To Initiate Amplification Of Cells For Treatment Of Pancreatic Cancer .................................................................................................................................................................................................. 313
Oct 30, 2012: AB Science Reports Phase III Study Results Of Masitinib In Combination With Gemzar For Treatment Of Pancreatic Cancer .................................................................................................................................................................... 313
Oct 25, 2012: Novelos Announces Enrollment Of First Patient In Solid Tumor Imaging Trial With I-124-CLR1404 At University Of Wisconsin Carbone Cancer Center .................................................................................................................... 315
Oct 24, 2012: Oncolytics Completes Patient Enrollment In US Phase II Study Investigating Reolysin In Combination With Gemcitabine In Patients With Pancreatic Cancer .................................................................................................................... 316
Oct 22, 2012: Vaximm Completes Enrollment In Phase I/II Study Of Oral Cancer Therapeutic Vaccine VXM01 ................. 317
Appendix ............................................................................................................................................................................................. 318
Methodology .................................................................................................................................................................................. 318
Coverage ....................................................................................................................................................................................... 318
Secondary Research ..................................................................................................................................................................... 318
Primary Research .......................................................................................................................................................................... 318
Expert Panel Validation ................................................................................................................................................................. 318
Disclaimer ...................................................................................................................................................................................... 319
List of Tables
Number of Products Under Development for Pancreatic Cancer, H1 2013 ........................................................................................ 16
Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2013 ................................................................... 17
Number of Products under Development by Companies, H1 2013 .................................................................................................... 19
Number of Products under Development by Companies, H1 2013 (Contd..1) ................................................................................... 20
Number of Products under Development by Companies, H1 2013 (Contd..2) ................................................................................... 21
Number of Products under Development by Companies, H1 2013 (Contd..3) ................................................................................... 22
Number of Products under Development by Companies, H1 2013 (Contd..4) ................................................................................... 23
Number of Products under Development by Companies, H1 2013 (Contd..5) ................................................................................... 24
Number of Products under Development by Companies, H1 2013 (Contd..6) ................................................................................... 25
Number of Products under Development by Companies, H1 2013 (Contd..7) ................................................................................... 26
Number of Products under Development by Companies, H1 2013 (Contd..8) ................................................................................... 27
Number of Products under Development by Companies, H1 2013 (Contd..9) ................................................................................... 28
Number of Products under Development by Companies, H1 2013 (Contd..10) ................................................................................. 29
Number of Products under Development by Companies, H1 2013 (Contd..11) ................................................................................. 30
Number of Products under Development by Companies, H1 2013 (Contd..12) ................................................................................. 31
Number of Products under Investigation by Universities/Institutes, H1 2013 ..................................................................................... 33
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) .................................................................... 34
Comparative Analysis by Late Stage Development, H1 2013 ............................................................................................................ 35
Comparative Analysis by Mid Clinical Stage Development, H1 2013 ................................................................................................. 36
![Page 9: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/9.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(9)
Comparative Analysis by Early Clinical Stage Development, H1 2013 .............................................................................................. 37
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 ......................................................................... 38
Products under Development by Companies, H1 2013 ...................................................................................................................... 39
Products under Development by Companies, H1 2013 (Contd..1) ..................................................................................................... 40
Products under Development by Companies, H1 2013 (Contd..2) ..................................................................................................... 41
Products under Development by Companies, H1 2013 (Contd..3) ..................................................................................................... 42
Products under Development by Companies, H1 2013 (Contd..4) ..................................................................................................... 43
Products under Development by Companies, H1 2013 (Contd..5) ..................................................................................................... 44
Products under Development by Companies, H1 2013 (Contd..6) ..................................................................................................... 45
Products under Development by Companies, H1 2013 (Contd..7) ..................................................................................................... 46
Products under Development by Companies, H1 2013 (Contd..8) ..................................................................................................... 47
Products under Development by Companies, H1 2013 (Contd..9) ..................................................................................................... 48
Products under Development by Companies, H1 2013 (Contd..10) ................................................................................................... 49
Products under Development by Companies, H1 2013 (Contd..11) ................................................................................................... 50
Products under Development by Companies, H1 2013 (Contd..12) ................................................................................................... 51
Products under Development by Companies, H1 2013 (Contd..13) ................................................................................................... 52
Products under Development by Companies, H1 2013 (Contd..14) ................................................................................................... 53
Products under Development by Companies, H1 2013 (Contd..15) ................................................................................................... 54
Products under Development by Companies, H1 2013 (Contd..16) ................................................................................................... 55
Products under Development by Companies, H1 2013 (Contd..17) ................................................................................................... 56
Products under Development by Companies, H1 2013 (Contd..18) ................................................................................................... 57
Products under Development by Companies, H1 2013 (Contd..19) ................................................................................................... 58
Products under Investigation by Universities/Institutes, H1 2013 ....................................................................................................... 59
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) ...................................................................................... 60
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) ...................................................................................... 61
Bristol-Myers Squibb Company, H1 2013 ............................................................................................................................................ 62
F. Hoffmann-La Roche Ltd., H1 2013 .................................................................................................................................................. 63
Amgen Inc., H1 2013............................................................................................................................................................................ 64
Sanofi-Aventis, H1 2013 ...................................................................................................................................................................... 65
AstraZeneca PLC, H1 2013 ................................................................................................................................................................. 66
Eli Lilly and Company, H1 2013 ........................................................................................................................................................... 67
Viralytics Ltd., H1 2013 ........................................................................................................................................................................ 68
GlaxoSmithKline plc, H1 2013 ............................................................................................................................................................. 69
Tekmira Pharmaceuticals Corp., H1 2013 ........................................................................................................................................... 70
Genentech, Inc., H1 2013 .................................................................................................................................................................... 71
Gilead Sciences, Inc., H1 2013 ............................................................................................................................................................ 72
Biotest AG, H1 2013 ............................................................................................................................................................................. 73
AbGenomics International, Inc., H1 2013 ............................................................................................................................................ 75
Plexxikon Inc., H1 2013 ....................................................................................................................................................................... 77
FibroGen, Inc., H1 2013 ....................................................................................................................................................................... 78
MediGene AG, H1 2013 ....................................................................................................................................................................... 79
Nanotherapeutics, Inc., H1 2013 ......................................................................................................................................................... 80
Prolexys Pharmaceuticals, Inc., H1 2013 ............................................................................................................................................ 81
ZIOPHARM Oncology, Inc., H1 2013 .................................................................................................................................................. 82
![Page 10: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/10.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(10)
Novartis AG, H1 2013 .......................................................................................................................................................................... 83
Samyang Corporation, H1 2013 .......................................................................................................................................................... 84
Aphios Corporation, H1 2013 ............................................................................................................................................................... 85
Astellas Pharma Inc., H1 2013 ............................................................................................................................................................ 86
CK Life Sciences Int'l., (Holdings) Inc., H1 2013 ................................................................................................................................. 87
Eisai Co., Ltd., H1 2013 ....................................................................................................................................................................... 88
SuperGen, Inc., H1 2013 ..................................................................................................................................................................... 89
Taiho Pharmaceutical Co., Ltd., H1 2013 ............................................................................................................................................ 90
Zeria Pharmaceutical Co Ltd, H1 2013 ................................................................................................................................................ 91
Exelixis, Inc., H1 2013 .......................................................................................................................................................................... 93
Aduro BioTech, H1 2013 ...................................................................................................................................................................... 94
Celgene Corporation, H1 2013 ............................................................................................................................................................ 95
Bayer AG, H1 2013 .............................................................................................................................................................................. 96
Incyte Corporation, H1 2013 ................................................................................................................................................................ 97
Halozyme Therapeutics, H1 2013 ........................................................................................................................................................ 98
Merck KGaA, H1 2013 ......................................................................................................................................................................... 99
Advaxis, Inc., H1 2013 ....................................................................................................................................................................... 100
EntreMed, Inc., H1 2013 .................................................................................................................................................................... 101
Anavex Life Sciences Corp., H1 2013 ............................................................................................................................................... 103
ValiRx Plc, H1 2013 ........................................................................................................................................................................... 104
ImmunoCellular Therapeutics, Ltd., H1 2013 .................................................................................................................................... 105
IMMUNOMEDICS, INC, H1 2013 ...................................................................................................................................................... 106
Lorus Therapeutics Inc, H1 2013 ....................................................................................................................................................... 107
Marshall Edwards, Inc., H1 2013 ....................................................................................................................................................... 108
MethylGene Inc, H1 2013 .................................................................................................................................................................. 109
Bionomics Limited, H1 2013 .............................................................................................................................................................. 110
Molecular Insight Pharmaceuticals, Inc., H1 2013 ............................................................................................................................ 111
Northwest Biotherapeutics, Inc., H1 2013 ......................................................................................................................................... 112
Oncolytics Biotech Inc., H1 2013 ....................................................................................................................................................... 113
Patrys Limited, H1 2013 ..................................................................................................................................................................... 114
Peregrine Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................ 115
Critical Outcome Technologies Inc., H1 2013 ................................................................................................................................... 116
La Jolla Pharmaceutical Company, H1 2013..................................................................................................................................... 117
Telik, Inc., H1 2013 ............................................................................................................................................................................ 118
VioQuest Pharmaceuticals, Inc., H1 2013 ......................................................................................................................................... 119
CytRx Corporation, H1 2013 .............................................................................................................................................................. 120
Champions Biotechnology, Inc., H1 2013 .......................................................................................................................................... 121
Oncogenex Pharmaceuticals, Inc., H1 2013 ..................................................................................................................................... 122
Pharmacyclics, Inc., H1 2013 ............................................................................................................................................................ 123
ProMetic Life Sciences Inc., H1 2013 ................................................................................................................................................ 124
Green Cross Corporation, H1 2013 ................................................................................................................................................... 125
OncoTherapy Science, Inc., H1 2013 ................................................................................................................................................ 126
Quest PharmaTech Inc., H1 2013 ..................................................................................................................................................... 127
Threshold Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................ 128
![Page 11: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/11.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(11)
Synta Pharmaceuticals Corp., H1 2013 ............................................................................................................................................. 129
CrystalGenomics, Inc., H1 2013 ........................................................................................................................................................ 130
Natco Pharma Limited, H1 2013 ........................................................................................................................................................ 131
Sareum Holdings plc, H1 2013 .......................................................................................................................................................... 132
DiaMedica Inc., H1 2013 .................................................................................................................................................................... 133
NanoCarrier Co., Ltd., H1 2013 ......................................................................................................................................................... 134
Rexahn Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................... 135
MabVax Therapeutics, Inc., H1 2013 ................................................................................................................................................ 136
Nanobiotix, H1 2013 ........................................................................................................................................................................... 137
Morphotek, Inc., H1 2013 ................................................................................................................................................................... 138
Cancer Research Technology Limited, H1 2013 ............................................................................................................................... 139
Antisense Pharma GmbH, H1 2013 ................................................................................................................................................... 140
Colby Pharmaceutical Company, H1 2013 ........................................................................................................................................ 141
Wilex AG, H1 2013 ............................................................................................................................................................................. 142
INSYS Therapeutics, Inc., H1 2013 ................................................................................................................................................... 143
Aurigene Discovery Technologies Limited, H1 2013 ......................................................................................................................... 144
Philogen S.p.A., H1 2013 ................................................................................................................................................................... 145
Multimmune GmbH, H1 2013............................................................................................................................................................. 146
Nerviano Medical Sciences S.r.l., H1 2013 ....................................................................................................................................... 147
Wellstat Therapeutics Corporation, H1 2013 ..................................................................................................................................... 148
Hutchison MediPharma Limited, H1 2013 ......................................................................................................................................... 149
ERYtech Pharma, H1 2013 ................................................................................................................................................................ 150
Alethia Biotherapeutics Inc., H1 2013 ................................................................................................................................................ 152
NormOxys, Inc., H1 2013 ................................................................................................................................................................... 153
Ascenta Therapeutics, Inc., H1 2013 ................................................................................................................................................. 154
Gene Signal International SA., H1 2013 ............................................................................................................................................ 155
Heat Biologics, Inc., H1 2013 ............................................................................................................................................................. 156
MacroGenics, Inc., H1 2013............................................................................................................................................................... 157
Antyra, Inc., H1 2013.......................................................................................................................................................................... 158
OncoMed Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................ 159
TetraLogic Pharmaceuticals, H1 2013 ............................................................................................................................................... 160
Azaya Therapeutics, Inc., H1 2013 .................................................................................................................................................... 161
Merrimack Pharmaceuticals, Inc., H1 2013 ....................................................................................................................................... 162
INNOPHARMAX, INC., H1 2013 ....................................................................................................................................................... 164
RESprotect GmbH, H1 2013 .............................................................................................................................................................. 165
Jennerex Biotherapeutics, Inc., H1 2013 ........................................................................................................................................... 166
Stemline Therapeutics, Inc., H1 2013 ................................................................................................................................................ 167
BioCancell Therapeutics, Inc., H1 2013 ............................................................................................................................................ 169
Cornerstone Pharmaceuticals, Inc., H1 2013 .................................................................................................................................... 170
Onconova Therapeutics, Inc, H1 2013 .............................................................................................................................................. 171
Pharminox Limited, H1 2013 .............................................................................................................................................................. 172
Viral Genetics, Inc., H1 2013 ............................................................................................................................................................. 173
KangLaiTe USA, H1 2013 .................................................................................................................................................................. 174
NovaLead Pharma Pvt. Ltd., H1 2013 ............................................................................................................................................... 175
![Page 12: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/12.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(12)
Esperance Pharmaceuticals, Inc., H1 2013 ....................................................................................................................................... 176
Omeros Corporation, H1 2013 ........................................................................................................................................................... 177
Transtech Pharma, Inc., H1 2013 ...................................................................................................................................................... 178
Welichem Biotech Inc., H1 2013 ........................................................................................................................................................ 179
Oncolys BioPharma Inc., H1 2013 ..................................................................................................................................................... 180
Globeimmune, Inc., H1 2013 ............................................................................................................................................................. 181
NewLink Genetics Corporation, H1 2013 .......................................................................................................................................... 182
Tragara Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................... 183
PharmaMar, S.A., H1 2013 ................................................................................................................................................................ 184
CG Therapeutics, Inc., H1 2013 ........................................................................................................................................................ 185
Quintessence Biosciences, Inc., H1 2013 ......................................................................................................................................... 186
AB Science, H1 2013 ......................................................................................................................................................................... 188
Tigris Pharmaceuticals, Inc., H1 2013 ............................................................................................................................................... 189
Genelux Corporation, H1 2013 .......................................................................................................................................................... 190
Lipopharma, H1 2013 ......................................................................................................................................................................... 191
Nereus Pharmaceuticals, Inc., H1 2013 ............................................................................................................................................ 192
Medisyn Technologies, Inc., H1 2013 ................................................................................................................................................ 193
Oncovir, Inc., H1 2013 ....................................................................................................................................................................... 194
Keystone Nano, Inc., H1 2013 ........................................................................................................................................................... 195
Perseus Proteomics, Inc., H1 2013 ................................................................................................................................................... 196
Pique Therapeutics, H1 2013 ............................................................................................................................................................ 197
3-V Biosciences, Inc., H1 2013 .......................................................................................................................................................... 198
Cancer Therapeutics CRC Pty Ltd, H1 2013 ..................................................................................................................................... 199
Eleison Pharmaceuticals, Inc., H1 2013 ............................................................................................................................................ 200
Targa Therapeutics Corp., H1 2013 .................................................................................................................................................. 201
KAEL-GemVax, H1 2013 ................................................................................................................................................................... 203
Nuvilex, Inc., H1 2013 ........................................................................................................................................................................ 204
iCeutica, Inc., H1 2013 ....................................................................................................................................................................... 205
Mebiopharm Co., Ltd., H1 2013 ......................................................................................................................................................... 206
Polaris Group, H1 2013 ...................................................................................................................................................................... 207
DEKK-TEC, Inc., H1 2013 .................................................................................................................................................................. 208
IkerChem S.L., H1 2013 ..................................................................................................................................................................... 209
Regulon Inc., H1 2013 ....................................................................................................................................................................... 210
TAU Therapeutics, LLC, H1 2013 ...................................................................................................................................................... 211
Gradalis Inc., H1 2013 ....................................................................................................................................................................... 212
CytoVac A/S, H1 2013 ....................................................................................................................................................................... 213
CytomX, LLC., H1 2013 ..................................................................................................................................................................... 215
Assessment by Monotherapy Products, H1 2013 ............................................................................................................................. 216
Assessment by Combination Products, H1 2013 .............................................................................................................................. 217
Assessment by Stage and Route of Administration, H1 2013 .......................................................................................................... 220
Assessment by Stage and Molecule Type, H1 2013 ......................................................................................................................... 223
Pancreatic Cancer Therapeutics – Drug Profile Updates .................................................................................................................. 269
Pancreatic Cancer Therapeutics – Discontinued Products ............................................................................................................... 293
Pancreatic Cancer Therapeutics – Discontinued Products (Contd..1) .............................................................................................. 294
![Page 13: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/13.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(13)
Pancreatic Cancer Therapeutics – Discontinued Products (Contd..2) .............................................................................................. 295
Pancreatic Cancer Therapeutics – Discontinued Products (Contd..3) .............................................................................................. 296
Pancreatic Cancer Therapeutics – Dormant Products ...................................................................................................................... 297
Pancreatic Cancer Therapeutics – Dormant Products (Contd..1) ..................................................................................................... 298
Pancreatic Cancer Therapeutics – Dormant Products (Contd..2) ..................................................................................................... 299
Pancreatic Cancer Therapeutics – Dormant Products (Contd..3) ..................................................................................................... 300
Pancreatic Cancer Therapeutics – Dormant Products (Contd..4) ..................................................................................................... 301
Pancreatic Cancer Therapeutics – Dormant Products (Contd..5) ..................................................................................................... 302
Pancreatic Cancer Therapeutics – Dormant Products (Contd..6) ..................................................................................................... 303
Pancreatic Cancer Therapeutics – Dormant Products (Contd..7) ..................................................................................................... 304
Pancreatic Cancer Therapeutics – Dormant Products (Contd..8) ..................................................................................................... 305
Pancreatic Cancer Therapeutics – Dormant Products (Contd..9) ..................................................................................................... 306
Pancreatic Cancer Therapeutics – Dormant Products (Contd..10) ................................................................................................... 307
Pancreatic Cancer Therapeutics – Dormant Products (Contd..11) ................................................................................................... 308
List of Figures
Number of Products under Development for Pancreatic Cancer, H1 2013 ........................................................................................ 16
Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2013 ................................................................... 17
Products under Development by Companies, H1 2013 ...................................................................................................................... 18
Products under Investigation by Universities/Institutes, H1 2013 ....................................................................................................... 32
Late Stage Products, H1 2013 ............................................................................................................................................................. 35
Mid Clinical Stage Products, H1 2013 ................................................................................................................................................. 36
Early Clinical Stage Products, H1 2013 ............................................................................................................................................... 37
Discovery and Pre-Clinical Stage Products, H1 2013 ......................................................................................................................... 38
Assessment by Monotherapy Products, H1 2013 ............................................................................................................................. 216
Assessment by Combination Products, H1 2013 .............................................................................................................................. 217
Assessment by Route of Administration, H1 2013 ............................................................................................................................ 218
Assessment by Stage and Route of Administration, H1 2013 .......................................................................................................... 219
Assessment by Molecule Type, H1 2013 .......................................................................................................................................... 221
Assessment by Stage and Molecule Type, H1 2013 ......................................................................................................................... 222
![Page 14: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/14.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(14)
Introduction
Global Markets Direct Report Coverage
Global Markets Direct’s, Pancreatic Cancer – Pipeline Review, H1 2013, provides an overview into the pipeline. This report provides information on the current developmental pipeline, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews the key players and their products under development for Pancreatic Cancer.
It is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
![Page 15: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/15.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(15)
Pancreatic Cancer Overview
Pancreatic carcinoma is cancer of the pancreas. The pancreas is a large organ located behind the stomach. It makes and releases enzymes into the intestines that help the body absorb foods, especially fats. Hormones called insulin and glucagon, which help your body control blood sugar levels, are made in special cells in the pancreas called islet cells. Tumors can also occur in these cells, but they are called islet cell tumors.
![Page 16: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/16.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(16)
Therapeutics Development
An Overview of Pipeline Products for Pancreatic Cancer
Number of Products under Development for Pancreatic Cancer, H1 2013
Source: Global Markets Direct
Number of Products Under Development for Pancreatic Cancer, H1 2013
Stage of Development Number of Products Under Development
Pre-Registration
Filing rejected/Withdrawn
Phase III
Phase II
Phase II
Phase I
Phase I
IND/CTA Filed
Preclinical
Discovery
Status Unknown
Total
Source: Global Markets Direct
![Page 17: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/17.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(17)
Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2013
Source: Global Markets Direct
Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2013
Stage of Development Company Universities/Institutes
Pre-Registration
Filing rejected/Withdrawn
Phase III
Phase II
Phase II
Phase I
Phase I
IND/CTA Filed
Preclinical
Discovery
Status Unknown
Total
Source: Global Markets Direct
![Page 18: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/18.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(18)
Pancreatic Cancer Therapeutics under Development by Companies
Products under Development by Companies, H1 2013
Source: Global Markets Direct
![Page 19: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/19.jpg)
SAMPLEPancreatic Cancer – Pipeline Review, H1 2013
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(19)
Number of Products under Development by Companies, H1 2013
Company Name Filed Phase III
Phase II
Phase I
Phase 0
IND Filed
Pre-Clinical
Discovery Status Unknown
Total
3-V Biosciences, Inc.
Ability Pharma, SL
Advaxis, Inc.
Alethia Biotherapeutics Inc.
Antisense Pharma GmbH
Antyra, Inc.
Apexigen, Inc.
APIM Therapeutics AS
Apogee Biotechnology Corporation
Arch Biopartners, Inc.
AREVA Med LLC
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Astrimmune
Source: Global Markets Direct
![Page 20: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/20.jpg)
SAMPLEAppendix
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(318)
Appendix
Methodology
Global Markets Direct dedicated Research and Analysis Teams consists of experienced professionals with a pedigree in marketing, market research, consulting background in the pharmaceutical industry and advanced statistical expertise.
Global Markets Direct adheres to the Codes of Practice of the Market Research Society (www.mrs.org.uk) and the Strategic and Competitive Intelligence Professionals (www.scip.org).
All Global Markets Direct databases are continuously updated and revised. The following research methodology is followed for all databases and reports.
Coverage
The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of the industry possible.
Changes the industry taxonomy are built on the basis of extensive research of company, association and competitor sources.Company coverage is based on three key factors: market capitalization, revenues and media attention/innovation/ market potential.An exhaustive search of 56 member exchanges is conducted and companies are prioritized on the basis of their market capitalization.The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage.Companies which are making the news, or which are of particular interest due to their innovative approach are prioritized.Global Markets Direct aims to cover all major news events and deals in the pharmaceutical industry, updated on a daily basis.The coverage is further streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below).
Secondary Research
The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market.The secondary research sources that are typically referred to include, but are not limited to:Company websites, annual reports, financial reports, broker reports, investor presentations and SEC FilingsIndustry trade journals and other literatureInternal and external proprietary databasesNational government documents, statistical databases and market reportsNews articles, press releases and web-casts specific to the companies operating in the market
Primary Research
Global Markets Direct conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis. A typical research interview fulfills the following functions:It provides first-hand information on the market size, market trends, growth trends, competitive landscape, future outlook etcHelps in validating and strengthening the secondary research findingsFurther develops the Analyses Team’s expertise and market understandingPrimary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies.The participants who typically take part in such a process include, but are not limited to:Industry participants: CEOs, VPs, business development managers, market intelligence managers and national sales managersOutside experts: Investment Bankers, Valuation Experts, Research Analysts and key opinion leaders specializing in pharmaceutical industry
Expert Panel Validation
Global Markets Direct uses a panel of experts to cross verify research and forecast methodologies, and drive its analytical content.The Global Markets Direct expert panel comprises of marketing managers, product specialists, international sales managers from pharmaceutical companies; academics from research universities and consultants from professional services companies. Details of the make up of the expert panel can be viewed through website, and are available to clients on request.
![Page 21: Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub](https://reader034.vdocuments.us/reader034/viewer/2022042404/5f1ba68cf4b32563800ef1b1/html5/thumbnails/21.jpg)
SAMPLE
Appendix
Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(319)
Disclaimer
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Global Markets Direct.